Assure Tech (Hangzhou) Co., Ltd. (688075.SS) has a MoatMap StockRank of 31/100 based on Quality (49/100), Value (32/100), and Momentum (37/100) factor scores. The current signal is SELL. Assure Tech is a small-cap in vitro diagnostics firm with no durable economic moat or pricing power in a post-pandemic market saturated with testing capacity.
Assure Tech (Hangzhou) Co., Ltd. specializes in the R&D, production, and sale of rapid in vitro diagnostic (IVD) reagents and instruments, focusing on POCT. The company operates an export-oriented business model with extensive international certifications (FDA, CE) for drug-of-abuse, infectious disease, and pregnancy testing. It is a globalized POCT manufacturer with strong cost advantages and rapid product commercialization capabilities.
| Price | $4.70 |
| Market Cap | $643M |
| P/E (TTM) | 164.60 |
| Price/Book | 0.81 |
| Return on Equity | 0.6% |
| Return on Invested Capital | 1.4% |
| Debt/Equity | 2.83 |
| Gross Margin | 105.9% |
| Operating Margin | -15.6% |
| Revenue Growth | -38.2% |
| Dividend Yield | 3.7% |
| Free Cash Flow | $933K |
Assure Tech (Hangzhou) Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).